Amgen Inc. (AMGN) reported robust earnings in its latest quarter, with a 9% revenue increase to approximately $9.9 billion in Q4 2025 and a 10% annual growth to around $36.8 billion. The biotech company is currently trading near its 52-week high, up about 8% in the most recent session, indicating strong investor interest.
Amgen’s stock has risen approximately 13.7% over the past three months and around 11% year-to-date. Notably, the forward price-to-earnings (P/E) ratio sits at 15.6x, suggesting that the stock is valued reasonably compared to the broader market, which has prompted analysts to raise price targets recently. RBC has set its target at $360, while Goldman Sachs has a target of $415.
Investors are particularly attentive to Amgen’s diversified portfolio and pipeline developments, which could lead to sustained revenue growth. For 2026, the consensus anticipates continued double-digit growth, with key metrics to watch including forward earnings per share progression, as the market reassesses the company’s valuation relative to its growth potential.
